ACAD
31.936
+0.496
+1.5782%
AEMD
1.517
+0.097
+6.8380%
APRI
1.5
+0.02
+1.35%
ARNA
21.02
0.00
0.00%
ATEC
1.916
-0.004
-0.208%
CNAT
5.16
-0.02
-0.39%
CRXM
0.172
0.00
0.00%
CYTX
0.318
-0.003
-0.837074%
DXCM
75.492
-0.418
-0.5503%
GNMK
9.385
-0.055
-0.583%
HALO
12.07
-0.03
-0.25%
ILMN
193.41
-1.35
-0.69%
INNV
0.115
-0.002
-1.709%
INO
5.575
+0.015
+0.270%
ISCO
1.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
127.51
-0.46
-0.36%
LPTN
2.93
-2.93
-100.00%
MBVX
0.47
-0.04
-7.7843%
MEIP
2.55
-0.03
-1.16%
MNOV
5.148
+0.098
+1.9327%
MRTX
5.05
-0.25
-4.72%
MSTX
0.13
-0.01
-5.28%
NBIX
52.11
-0.55
-1.04%
NUVA
63.71
-0.99
-1.53%
ONCS
0.924
-0.016
-1.702%
ONVO
1.889
-0.061
-3.128%
OREX
2.337
-0.003
-0.1154%
OTIC
20.275
-0.075
-0.369%
QDEL
32.97
-0.51
-1.52%
RCPT
231.96
0.00
0.00%
RGLS
0.91
+0.05
+5.8605%
RMD
74.035
-0.515
-0.691%
SCIE
0
0.00
0.00%
SPHS
1.9
+0.01
+0.53%
SRNE
1.675
-0.025
-1.471%
TROV
0.838
-0.012
-1.388942%
VICL
2.38
+0.01
+0.42%
VOLC
18
0.00
0.00%
ZGNX
12.75
+0.3
+2.41%
ACAD
31.936
+0.496
+1.5782%
AEMD
1.517
+0.097
+6.8380%
APRI
1.5
+0.02
+1.35%
ARNA
21.02
0.00
0.00%
ATEC
1.916
-0.004
-0.208%
CNAT
5.16
-0.02
-0.39%
CRXM
0.172
0.00
0.00%
CYTX
0.318
-0.003
-0.837074%
DXCM
75.492
-0.418
-0.5503%
GNMK
9.385
-0.055
-0.583%
HALO
12.07
-0.03
-0.25%
ILMN
193.41
-1.35
-0.69%
INNV
0.115
-0.002
-1.709%
INO
5.575
+0.015
+0.270%
ISCO
1.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
127.51
-0.46
-0.36%
LPTN
2.93
-2.93
-100.00%
MBVX
0.47
-0.04
-7.7843%
MEIP
2.55
-0.03
-1.16%
MNOV
5.148
+0.098
+1.9327%
MRTX
5.05
-0.25
-4.72%
MSTX
0.13
-0.01
-5.28%
NBIX
52.11
-0.55
-1.04%
NUVA
63.71
-0.99
-1.53%
ONCS
0.924
-0.016
-1.702%
ONVO
1.889
-0.061
-3.128%
OREX
2.337
-0.003
-0.1154%
OTIC
20.275
-0.075
-0.369%
QDEL
32.97
-0.51
-1.52%
RCPT
231.96
0.00
0.00%
RGLS
0.91
+0.05
+5.8605%
RMD
74.035
-0.515
-0.691%
SCIE
0
0.00
0.00%
SPHS
1.9
+0.01
+0.53%
SRNE
1.675
-0.025
-1.471%
TROV
0.838
-0.012
-1.388942%
VICL
2.38
+0.01
+0.42%
VOLC
18
0.00
0.00%
ZGNX
12.75
+0.3
+2.41%
Home » Archive by Category

Syndication

Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies

August 21, 2017 – 1:22 pm

New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional RegenerationContributions of Capital, More Than 200+ Issued and Pending Patents, Pre-Clinical and Clinical Assets and Commercial Products Obtained from Companies Including Celgene Corporation, Sorrento Therapeutics (Nasdaq: SRNE), United Therapeutics, and Human Longevity, Inc

SAN DIEGO, Aug. 21, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced that the transactions contemplated by the Contribution Agreement it entered with Celularity, Inc. (“Celularity”) has closed.  Sorrento previously announced that it together with its subsidiary, TNK Therapeutics, Inc. (“TNK”), had entered into a definitive agreement (“Contribution Agreement”) to offer certain immuno-oncology and cellular therapy intellectual property and assets to Celularity, a company being formed and run by former Celgene Cellular Therapeutics CEO, Robert Hariri, MD/PhD.

Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.

Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:

  • Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets
  • Proprietary allogeneic (“readily accessible”) immunotherapy platform
  • 200+ issued and pending patents in cell therapy; robust IP for placental stem cells
  • Broad fully human antibody-CAR constructs
  • IND-ready joint CD38 immuno-oncology programs
  • Commercial-stage functional regeneration products Biovance® and Interfyl®* and pipeline assets
  • LifeBankUSA stem cell biorepository with two decades operating expertise

Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity’s ability to procure placental stem cells, engineer potential therapies, and deploy potential treatments, positions it to harness the potential of the human placenta and operate along the entire value chain.

“Celularity was formed as a new biotechnology model designed to apply the necessary expertise to harness our placenta discovery platform across a range of unmet medical needs,” said Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. “With the support of our investors, we are assembling proven regenerative medicine technology and expertise with the goal of developing transformative therapies for fatal and intractable diseases.” Dr. Hariri was previously chairman, chief scientific officer and chief executive officer of Celgene Cellular Therapeutics and founder of Anthrogenesis Corporation, which Celgene acquired in 2002. Dr. Hariri is also the co-founder of Human Longevity, Inc.

The formation of Celularity leverages seminal work in the discovery of novel biologically active cell populations in the human placenta with broad therapeutic potential. Celularity will draw upon these proprietary and scalable discoveries that derive from the post-partum human placenta – an ethical and renewable source of usable biomaterials. Celularity’s development program is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a diverse population of informed-consent donors.

Andrew von Eschenbach, MD, among the founding members of the Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of the National Cancer Institute said, “The pioneering work of Celularity founder Bob Hariri has unleashed the unique properties of placental derived stem cells which have renewed hope for creating safe and effective therapies for the most challenging degenerative diseases.” Dr. von Eschenbach added, “Celularity with its focus on accelerating innovation in regenerative medicine can become the leading catalyst for cell therapy to address many of the world’s unmet medical needs.”

Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, “We are very excited to participate in the creation of Celularity together with Dr. Hariri and his scientific team as well as global leading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularity’s technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies.”

About Celularity, Inc.

Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses. For more information, please visit www.celularity.com. Follow Celularity on Social Media: @Celularity.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

About Human Longevity, Inc.

Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com

About Sorrento Therapeutics

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento’s multimodal multipronged approach to fighting cancer is made possible by its’ extensive Immuno-Oncology platform, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic viral vectors (“Seprehvir®”).

Sorrento’s commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid non-addictive pain management small molecule (“RTX/resiniferatoxin”). Resiniferatoxin is completing a phase Ib trial in terminal cancer patients. For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the developments of and prospects for Celularity, its products and technologies; Sorrento’s and TNK’s products and technologies, including their respective CAR, immune-therapy/immune-oncology and antibody products and technologies;  Sorrento’s ability to leverage the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its strategies; and other matters that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2016, as amended, and any subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.,  and G-MAB™ is a trademark owned by Sorrento Therapeutics, Inc.

Seprehvir®, is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.

Interfyl® is a registered trademark of Alliqua BioMedical, Inc.

© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/sorrento-contributes-to-the-formation-of-celularity-inc-for-breakthrough-placental-therapeutic-platform-in-consortium-with-leading-pharmaceutical-companies-300507324.html

SOURCE Sorrento Therapeutics, Inc.

UC San Diego Astronomers Take Flight for Rare Solar Eclipse

August 21, 2017 – 1:12 pm

They are professional astronomers who travel the globe to study distant galaxies, Earth-like planets around other solar systems and the primordial radiation left over from the “Big Bang,” the explosive beginning of the universe.

CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting

August 21, 2017 – 5:00 am

Company Seeks to Avoid Delisting from NASDAQ

LOS ANGELES, Aug 21, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR) (“CytRx or “the Company”), a biopharmaceutical research and development company specializing in oncology, announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in connection with a planned special meeting of stockholders to authorize the Board of Directors to effect a reverse stock split of the Company’s common stock, if deemed necessary.  A reverse stock split may enable the Company to regain compliance with NASDAQ’s $1.00 minimum bid price requirement and maintain its listing on the NASDAQ Capital Market.

CytRx’s intent is to continue to be listed on the NASDAQ Capital Market.  In addition to sustaining a NASDAQ listing, the Company believes a higher share price resulting from a reverse stock split will help enlarge the shareholder base by expanding its appeal to institutional investors and as a result enhance long-term stockholder value.

As described in the preliminary proxy materials, a special meeting of CytRx stockholders will be held to consider the reverse stock split proposal.  The date of the special meeting will be announced in a definitive proxy statement to be mailed to stockholders and filed with the SEC.  Stockholders are urged to read the definitive proxy statement when it becomes available, because it will contain important information about CytRx and the proposed split.  Definitive proxy materials for the special meeting are expected to be mailed the week of September 5, 2017.

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed reverse stock split. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN ITS ENTIRETY THE PRELIMINARY PROXY STATEMENT FILED WITH THE SEC, AND, WHEN THEY BECOME AVAILABLE, THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS, BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED REVERSE STOCK SPLIT.  The definitive proxy statement will be mailed to stockholders as of a record date to be established for voting on the proposed reverse stock split. Stockholders may obtain free copies of the Company’s preliminary proxy statement and its other SEC filings electronically by accessing the SEC’s home page at http://www.sec.gov. Copies can also be obtained, free of charge, upon written request to CytRx Corporation, Attn: Corporate Secretary, 11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049. 

Participation in Solicitation

This press release may constitute soliciting material under SEC Rule 14a-12, and CytRx and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies from the holders of CytRx common stock in respect of the proposed reverse stock split. Investors may obtain additional information regarding the interest of those participants by reading the Company’s preliminary proxy statement and, when they become available, the Company’s definitive proxy statement and other relevant proxy materials, and the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q, as filed with the SEC.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor.  Aldoxorubicin, CytRx’s most advanced drug conjugate, is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc.  CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies.

Forward Looking Statements

This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to: plans for regaining compliance with the NASDAQ rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell Inc. to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell; our ability to develop new ultra-high potency drug candidates based on our LADR™ technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Media Contact:
Argot Partners
Eliza Schleifstein
(973) 361-1546
eliza@argotpartners.com   

Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com

 

View original content:http://www.prnewswire.com/news-releases/cytrx-corporation-files-preliminary-proxy-statement-for-upcoming-special-meeting-300506913.html

SOURCE CytRx Corporation

On Drug Pricing: FDA Backs Up Its Calls for Increased Competition

August 21, 2017 – 4:40 am

FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription…

[[Click headline to continue reading.]]

Forbes Ranks BioMarin 12th Most Innovative Company in the World

August 21, 2017 – 4:30 am

For the fourth consecutive year, BioMarin ranks in top 20 on list

SAN RAFAEL, Calif., Aug. 21, 2017 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 12th on Forbes magazine’s 2017 list of the “World’s Most Innovative Companies.” BioMarin, a pharmaceutical company focused on rapidly developing and delivering first-in-class or best-in-class therapies for those with severe rare diseases, is dedicated to providing therapies for unmet medical needs.

This is the fourth consecutive year that BioMarin has received the recognition, acknowledging the company’s commitment to making an impact in the lives of small patient populations. The two previous years the company was ranked 10th and in 2014, the company ranked 7th.

“We are honored to receive this recognition from Forbes each year amongst so many notable and worthy companies,” said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin. “In 2017, we continue to advance our innovative portfolio to serve patients with rare genetic diseases, now with six therapies on the market. This year also marks the company’s 20th year of making a big difference for small patient populations.”

Forbes’ rankings are based on the companies’ ‘innovation premium’ which is a measure of how much investors have bid up the stock price of a company above the value of its existing businesses based on expectations of future innovative results, products, services and markets. To qualify, the businesses must have at least seven years of financial data and a market value greater than $10 billion, and have measurable investment in research and development.

To view the complete list click here.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company’s portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.biomarin.com. Information on BioMarin’s website is not incorporated by reference into this press release.

Contact:

Investors:

Media:

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

View original content with multimedia:http://www.prnewswire.com/news-releases/forbes-ranks-biomarin-12th-most-innovative-company-in-the-world-300506837.html

SOURCE BioMarin Pharmaceutical Inc.

Manager, Chemistry – Conatus Pharmaceuticals – San Diego, CA

August 20, 2017 – 5:07 pm

Experience on the strategic business side of public biotech companies preferred. Provide guidance and expertise in the development of new compounds by managing…From Indeed – Mon, 21 Aug 2017 01:07:13 GMT – View all San Diego, CA jobs

Senior Technical Writer – Illumina – San Diego, CA

August 19, 2017 – 10:46 pm

Quickly learn and apply new tools, processes, and standards. You have an eye for detail and consistency, and exhibit unfailing attention to quality construction…From Illumina – Sun, 20 Aug 2017 06:46:11 GMT – View all San Diego, CA jobs

Tech, Manufacturing 2 – EMD – Carlsbad, CA

August 19, 2017 – 12:09 am

It offers a broad range of innovative products and services to biotech and pharmaceutical drug therapies businesses….From EMD – Sat, 19 Aug 2017 08:09:34 GMT – View all Carlsbad, CA jobs

Tech, Manufacturing 3 – EMD – Carlsbad, CA

August 19, 2017 – 12:09 am

It offers a broad range of innovative products and services to biotech and pharmaceutical drug therapies businesses….From EMD – Sat, 19 Aug 2017 08:09:34 GMT – View all Carlsbad, CA jobs

Quality Assurance Associate (San Diego)

August 18, 2017 – 5:20 pm

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t …